Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Financials, Oil & Gas and Technology sectors led shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Technology, Industrials and Consumer Services sectors led shares higher. At the close in NYSE,...
By Sam Boughedda Investing.com — Catalyst Biosciences Inc (NASDAQ:CBIO) shares tumbled more than 40% after it told investors it has made a strategic decision to discontinue the...
Cigna Corporation (NYSE:CI) CI is set to report first-quarter 2021 results on May 7, before the opening bell.In the fourth quarter of 2020, the company’s earnings of $3.51...
Shares of Conagra Brands, Inc. (NYSE:CAG) surged 15.9% after the company reported Q2 fiscal 2020 earnings of 63 cents per share, which beat the Zacks Consensus Estimate of 57...
Shares of Constellation Brands, Inc. (NYSE:STZ) dropped 6.1% after the company took an $839 million markdown in the value of its investment in Canopy Growth Corporation...
Catalyst Biosciences, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. The Company's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT. The Company's product MarzAA is a subcutaneously (SQ) administered next generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. The Company's DalcA is a next generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. Its CB 2679d-GT is an Adeno-associated virus (AAV)-based gene therapy construct harboring the DalcA sequence. The Company's SQ product candidates demonstrate a prolonged duration of activity enabling them to provide continuous therapeutic levels.
| Average | 15.500 (+2975.40% Upside) |
| High | 16 |
| Low | 15 |
| Price | 0.504 |
| No. of Analysts | 2 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Strong Sell | Sell | Strong Sell |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 265.25 | 275.57 | 262.47 | -2.96 | -1.10% | 66.83M | NASDAQ | |||
| 43.76 | 44.60 | 43.73 | -0.40 | -0.91% | 22.87M | NYSE | |||
| 113.00 | 116.92 | 112.84 | -1.80 | -1.57% | 58.90M | NASDAQ | |||
| 187.11 | 193.90 | 186.60 | -3.95 | -2.07% | 446.14K | NASDAQ | |||
| 3.46 | 3.61 | 3.38 | +0.05 | +1.47% | 375.28K | NASDAQ | |||
| 83.12 | 86.20 | 82.50 | -12.21 | -12.81% | 47.92M | NYSE | |||
| 11.01 | 11.54 | 10.36 | +0.15 | +1.38% | 1.65M | NYSE | |||
| 37.97 | 38.79 | 37.95 | -0.67 | -1.73% | 23.40M | NYSE | |||
| 177.65 | 182.92 | 177.60 | -2.41 | -1.34% | 9.44M | NYSE | |||
| 54.91 | 54.91 | 53.22 | +2.257 | +4.29% | 8.04K | OTC Markets | |||
| 0.0594 | 0.0594 | 0.049 | +0.0214 | +56.32% | 6.60K | NYSE | |||
| 2.75 | 2.91 | 2.75 | -0.11 | -3.85% | 11.86M | NASDAQ | |||
| 156.34 | 159.20 | 154.46 | -3.32 | -2.08% | 574.52K | NYSE | |||
| 63.36 | 65.91 | 63.34 | -0.78 | -1.22% | 79.76M | NASDAQ | |||
| 39.86 | 40.10 | 39.11 | +0.77 | +1.97% | 1.57M | NYSE |